Pulmonary Fibrosis Biotech Avalyn Pharma Files For IPO

Pulmonary fibrosis developer Avalyn Pharma's April 2026 IPO filing arrives at a pivotal moment for specialty pharma: the company is betting public markets will fund late-stage development of inhaled formulations of approved oral therapies precisely when traditional biotech venture capital faces its